Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis

MA Arce-Huamani, JJ Barboza, JF Martínez-Herrera… - Medicina, 2023 - mdpi.com
Background and Objectives: Venous thromboembolism (VTE) is common in cancer patients.
Anticoagulant therapy with low-molecular-weight heparins (LMWHs) and direct oral …

DOAC in the treatment of cancer-associated venous thromboembolism: a retrospective cohort study beyond the guidelines

M Cominacini, S Suardi, G Ferrari, R Ciresa… - Journal of Cancer …, 2023 - Springer
Background The emerging use of direct oral anticoagulants (DOAC) in the management of
cancer-associated venous thromboembolism (CAT) is significantly improving therapeutic …

Safety and efficacy of direct oral anticoagulants for treatment of venous thromboembolism in pediatric oncology patients

A Scheuermann, M Liegl, P Simpson… - Journal of Pediatric …, 2023 - journals.lww.com
Methods: We performed a single-center, retrospective review of children 0 to 20 years of age
from 2012 to 2020 with malignancy and confirmed VTE, with the objective to evaluate the …

[PDF][PDF] " Choix du traitement anticoagulant pour les patients présentant un évènement thrombotique dans un contexte oncologique: revue systématique et méta …

A ROSSEL - access.archive-ouverte.unige.ch
Archive ouverte UNIGE Choix du traitement anticoagulant pour les patients présentant un
évènement thrombotique dans un contex Page 1 Archive ouverte UNIGE https://archive-ouverte.unige.ch …